Chronocort 5mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
81	先天性副腎皮質酵素欠損症	1

81. 先天性副腎皮質酵素欠損症

---

臨床試験数 : 87 /  薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-004467-26-FR (EUCTR)		09/12/2021	An Open-label Extension Study to Evaluate the Long-term Safety andTolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia	A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety andTolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Efmody 5 mg modified release hard capsules Product Name: Chronocort 5mg INN or Proposed INN: HYDROCORTISONE Other descriptive name: HYDROCORTISONE MICRONIZED Trade Name: Efmody 10 mg modified release hard capsules Product Name: Chronocort 10mg INN or Proposed INN: hydrocortisone Other descriptive name: HYDROCORTISONE MICRONIZED	Diurnal Limited	NULL	NA			Female: yes Male: yes	181	Phase 3	United States;France;Japan